rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
An increase in breast cancer-specific mortality was observed for carriers of the germline MDM2 SNP309 rare GG-genotype (range hazard ratios: 2-3) or TP53 R72P heterozygous GC-genotype (range hazard ratios: 1-2) compared to those having the common genotypes within subgroups of tumors displaying a "more aggressive phenotype" gene expression profile.
|
21667122 |
2011 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
|
21706156 |
2012 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Taken together, we showed the preferential loss of the rs1042522 C allele, which is protective against BC progression, in breast tumors.
|
21810023 |
2011 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The G allele of the TP53 R72P polymorphism and T allele of the MDM2 SNP309 polymorphism were putative high-risk alleles and exhibited a combined gene-dose-dependent joint effect on breast cancer risk that was more clearly observed in postmenopausal women.
|
21833626 |
2011 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the stratified analyses, a significant association between MDM2 SNP309 and breast cancer</span> risk were observed in Asian, but null significant association between TP53 R72P and breast cancer risk were found even in various subgroups.
|
22729912 |
2012 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we investigated the effect on breast cancer survival of germline variation in these genes in 925 Finnish breast cancer patients and further analyzed five single nucleotide polymorphisms (SNPs) in PRKAG2 (rs1029946, rs4726050, rs6464153, rs7789699) and PPP2R2B (rs10477313) for 10-year survival in breast cancer patients, interaction with TP53 R72P and MDM2-SNP309, outcome after specific adjuvant therapy and correlation to tumor characteristics in 4,701 invasive cases from four data sets.
|
23034890 |
2013 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.
|
23716179 |
2013 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interestingly, we observed a combinational effect between MDM4 rs4245739 and P53 Arg72Pro variants in attenuating breast cancer risk, highlighting the importance of the P53 tumor suppressor pathway genes during malignant transformation.
|
23793604 |
2013 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
RAD51 135G>C and TP53 Arg72Pro polymorphisms and susceptibility to breast cancer in Serbian women.
|
24114315 |
2014 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The results of present study indicated that among the five TP53 polymorphisms investigated, the p.R72P polymorphism, and the RP-A1A1 and RP-GG genotype combination contribute to breast cancer susceptibility in North Indians.
|
25169539 |
2014 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results indicated a statistically significant association (p<0.05) between rs1219648, but not rs1042522, and risk of breast cancer.
|
25292094 |
2014 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genetic data revealed that the p53 Arg72Pro genotype was found to be greatly associated with breast cancer risk (p<0.001), as well as tumor site (p=0.046).
|
25750340 |
2015 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Arg72Pro and PIN3(16bp duplication) polymorphisms are proposed to have an effective role in structural changes of p53 and have therefore attracted interest as a risk factor for breast cancer in different populations.
|
25854391 |
2015 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our finding suggests that TP53 (Arg72Pro) polymorphism may play a significant role as risk factor for breast cancer in north Indian breast cancer patients.
|
26553387 |
2016 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A significant association was found between TP53Arg72Pro (rs1042522) and CDH1 -160 C/A (rs16260) polymorphisms and breast cancer risk.
|
26666818 |
2016 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study investigates the role of 3 nonsynonymous SNPs in the DNA repair genes XRCC1 (R399Q), RAD51 (G135C) and TP53 (Arg72Pro) in breast cancer in Serbian women.
|
26954070 |
2016 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, the results obtained from the combination of SNPs 344T>A of MDM2 and 72 Arg/Pro of p53, do not support the hypothesis of the prominent role of common p53 and MDM2 variations in the genetic mechanisms of chemotherapy resistance in breast cancer.
|
27569097 |
2016 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The frequency of the rs1042522 polymorphism of TP53 was significantly higher in all groups of patients with breast cancer compared with the control group.
|
27644661 |
2016 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Allele 399Gln (OR 1.57; 95% CI 1.05-2.35), Arg399Gln of gene XRCC1 heterozygous genotype (OR 2.77; 95% CI 1.60-4.80), the combination of Arg399Gln/Arg72Pro of genes XRCC1/TP53 heterozygous genotype (OR 3.98; 95% CI 1.57-10.09), Arg399Gln/T309G of genes XRCC1/MDM2 (OR 3.0; 95% CI 1.18-7.56), as well as Arg399Gln/Arg72Pro/T309G of genes XRCC1/TP53/MDM2 (OR 6.40; 95% CI 1.18-34.63) were associated with BC in Kyrgyz women.
|
29132330 |
2017 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results suggest that TP53 c.215G>C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to BC in Moroccan population.
|
29949804 |
2018 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The findings of our case-control study and meta-analysis suggest a significant association between p53 Arg72Pro polymorphism and an increased risk of breast cancer in Indian population.
|
30065615 |
2018 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
A total of 5 tagging single-nucleotide polymorphisms (rs2299941 of PTEN, rs2735385, rs6999227, rs1805812, and rs1061302 of Nijmegen breakage syndrome 1) were tightly associated with breast cancer risk in sporadic cases, and 5 other tagging single-nucleotide polymorphisms (rs1042522 of TP53, rs2735343 of PTEN, rs7220719, rs16945628, and rs11871753 of BRCA1-interacting protein 1) were tightly associated with breast cancer risk in familial and early-onset cases.
|
30799775 |
2018 |
rs1042522
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
These findings cannot support contribution of rs1042522 polymorphism to breast cancer risk in an Iranian population.
|
31721533 |
2020 |